Search Results for “diabetes” – Page 51 – media

How to turn damaged heart tissue back into healthy heart muscle—new details emerge

Now, in a new study published today in Nature, UNC researchers report a breakthrough. They have used single cell RNA sequencing technology in combination with mathematical modeling and genetic and chemical approaches to delineate the step-by-step molecular changes that occur during cell fate conversion from fibroblast to cardiomyocyte.
- Source: medicalxpres
- 580
- October 26, 2017
cardiology regenerative medicine
Abbott rolls out smartphone-connected ICM in the U.S.

The FDA has cleared Abbott’s smartphone-compatible insertable cardiac monitor (ICM), the first and only device of its kind in the U.S. This provides patients and physicians with another way to monitor and diagnose abnormal heart rhythms.
- Source: Guidedsolutions
- 594
- October 25, 2017
heart rhythms ICM New Approvals
New synthetic genetic tool measures and manipulates protein aggregation in live cells

A common thread ties seemingly unlinked disorders like Alzheimer's disease and type II diabetes together. This thread is known as protein aggregation and happens when proteins clump together. These complexes are a hallmark of many diseases, but have recently been linked to beneficial functions as well.
- Source: news-medical
- 398
- October 25, 2017
prions protein aggregation
Drug delivery devices market in India to reach $510m by 2023

The drug delivery devices market in India is expected to rise at a compound annual growth (CAGR) of 3.1% from $411m in 2016 to $510m by 2023, according to a report by GlobalData.
- Source: medicaldevice-network
- 392
- October 23, 2017
drug delivery devices India Market Views
Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee

Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. One member of the committee abstained.
- Source: finance.yahoo
- 609
- October 20, 2017
diabetes FDA New Approvals semaglutide
Hormone therapy for prostate cancer increases cardiac risk

Androgen-deprivation therapy, which is a common treatment for prostate cancer, has been tentatively linked with an increased risk of cardiovascular disease. A new study solidifies these concerns.
- Source: medicalnewstoday
- 612
- October 19, 2017
cancer cardiovascular prostate Researches
Big Pharma Gets Boost as China Speeds Up New Drug Approvals

For decades, Chinese patients have struggled to gain access to cutting-edge medicines thanks to bureaucratic delays that have hamstrung drug development. Now a sweeping government overhaul of drug approvals is poised to change that.
- Source: bloomberg
- 512
- October 10, 2017
Chinese drug approval Market Views
FDA approves first continuous glucose monitoring system for adults not requiring blood sample calibration

The U.S. Food and Drug Administration(FDA) approved the FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adult patients to make diabetes treatment decisions without calibration using a blood sample from the fingertip (often referred to as a “fingerstick”).
- Source: fda.gov
- 838
- September 30, 2017
FDA Glucose Monitoring System New Approvals
Two Scientists Nab Another $20 Million for Their CRISPR Biotech Eligo Bioscience

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge. This comes just months after Eligo was selected as one of the 30 Most Innovative Companies in 2017 by the World Economic Forum. This funding will enable Eligo to strengthen its biotherapeutic platform, begin clinical trials for its lead indication and extensively grow its international team of scientists, engineers, and executives.
- Source: Biospace
- 525
- September 29, 2017
Market Views microbiome Series
Novo Nordisk’s new-generation basal insulin Tresiba® approved in China

Novo Nordisk announced that the China Food and Drug Administration (CFDA) has approved Tresiba® (insulin degludec) for the treatment of diabetes in China. Tresiba® is a new-generation, once-daily basal insulin with an ultra-long duration of action which allows for flexibility in day-to-day dosing.
- Source: Novonordisk
- 544
- September 29, 2017
CFDA diabetes New Approvals Tresiba

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.